Clinical Trial Update: A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC [Phase 2]

View source ↗

Summary

This update describes a Phase II trial comparing AK104 in combination with lenvatinib versus lenvatinib alone for second-line hepatocellular carcinoma, which is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Akeso | Conditions: HCC, Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING